Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis

Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis

Abstract Background To evaluate a new UGT1A and DPYD polymorphism panel to better predict irinotecan-induced toxicity and the clinical response in Chinese patients with metastatic colorectal cancer (mCRC). Methods The genotypes of UGT1A (UGT1A1*6, UGT1A1*27, UGT1A1*28, UGT1A7*2, UGT1A7*3, UGT1A7*4 a...

Full description

Bibliographic Details
Main Authors: Dan Liu, Jian Li, Jing Gao, Yanyan Li, Rui Yang, Lin Shen
Format: Article
Language:English
Published: BMC 2017-06-01
Series:BMC Cancer
Subjects:
Irinotecan
UGT1A polymorphisms
DPYD polymorphisms
Metastatic colorectal cancer
Toxicity
Clinical response
Online Access:http://link.springer.com/article/10.1186/s12885-017-3406-2

Internet

http://link.springer.com/article/10.1186/s12885-017-3406-2

Similar Items